Effect of Polyarginine Peptide R18D Following a Traumatic Brain Injury in Sprague-Dawley Rats

ABSTRACT: Background: Despite extensive studies, there are still no clinically available neuroprotective treatments for traumatic brain injury. Objectives: In previous studies we demonstrated beneficial treatment effects of polyarginine peptides R18 (18-mer of arginine; 300 nmol/kg) and R18D (18-mer...

Full description

Saved in:
Bibliographic Details
Main Authors: Li Shan Chiu, PhD (Author), Ryan S. Anderton, PhD (Author), Vince W. Clark, MSc (Author), Jane L. Cross, PhD (Author), Neville W. Knuckey, MBBS (Author), Bruno P. Meloni, PhD (Author)
Format: Book
Published: Elsevier, 2020-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3ad2c75133cc4d0aa3ebb9dc9cd2e0a2
042 |a dc 
100 1 0 |a Li Shan Chiu, PhD  |e author 
700 1 0 |a Ryan S. Anderton, PhD  |e author 
700 1 0 |a Vince W. Clark, MSc  |e author 
700 1 0 |a Jane L. Cross, PhD  |e author 
700 1 0 |a Neville W. Knuckey, MBBS  |e author 
700 1 0 |a Bruno P. Meloni, PhD  |e author 
245 0 0 |a Effect of Polyarginine Peptide R18D Following a Traumatic Brain Injury in Sprague-Dawley Rats 
260 |b Elsevier,   |c 2020-01-01T00:00:00Z. 
500 |a 0011-393X 
500 |a 10.1016/j.curtheres.2020.100584 
520 |a ABSTRACT: Background: Despite extensive studies, there are still no clinically available neuroprotective treatments for traumatic brain injury. Objectives: In previous studies we demonstrated beneficial treatment effects of polyarginine peptides R18 (18-mer of arginine; 300 nmol/kg) and R18D (18-mer of D-arginine; 1000 nmol/kg) in a rat model of impact-acceleration closed-head injury. Methods: We examined the efficacy of R18D when intravenously administered at a low (100 nmol/kg) and high (1000 nmol/kg) dose, 30 minutes after a closed-head injury in male Sprague-Dawley rats. Results: At postinjury day 3, treatment with R18D at the high dose significantly reduced axonal injury (P = 0.044), whereas the low-dose treatment of R18D showed a trend for reduced axonal injury. Following assessment in the Barnes maze, both doses of R18D treatment appeared to improve learning and memory recovery compared with vehicle treatment at postinjury days 1 and 3, albeit not to a statistically significant level. Rotarod assessment of vestibulomotor recovery did not differ between R18D and the vehicle treatment groups. Conclusions: R18D modestly decreased axonal injury only at the highest dose used but had no significant effect on functional recovery. These findings warrant further studies with additional doses to better understand peptide pharmacodynamics and provide information to guide optimal dosing. 
546 |a EN 
690 |a Cationic arginine-rich peptides 
690 |a Diffuse axonal injury 
690 |a Neuroprotection 
690 |a R18D 
690 |a TBI 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Current Therapeutic Research, Vol 92, Iss , Pp 100584- (2020) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S0011393X20300102 
787 0 |n https://doaj.org/toc/0011-393X 
856 4 1 |u https://doaj.org/article/3ad2c75133cc4d0aa3ebb9dc9cd2e0a2  |z Connect to this object online.